A randomized, double-blind, placebo-controlled, multicenter dose ranging study of ALX-0171 in infants and young children hospitalized for respiratory syncytial virus lower respiratory tract infection
Phase of Trial: Phase II
Latest Information Update: 04 Oct 2017
At a glance
- Drugs ALX 0171 (Primary)
- Indications Respiratory syncytial virus infections
- Focus Therapeutic Use
- Acronyms Respire
- Sponsors Ablynx
- 24 Aug 2017 According to an Ablynx media release, the sequential dose escalation part of the has been completed in 36 infants hospitalised as a result of a respiratory syncytial virus (RSV) infection and the parallel dose part has been initiated subsequently with the aim to recruit an additional 144 infants, after a positive recommendation from the Data Monitoring Committee (DMC).
- 24 Aug 2017 According to an Ablynx media release, topline results from the study are expected in the second half of 2018.
- 11 Jan 2017 According to an Ablynx media release, top-line results from this trial are expected in the second half of 2018.